JAMA肿瘤学:不吃夜宵能降低乳腺癌复发率?
药明康德 · 2016/04/24
很多人喜欢吃夜宵。不过,在看完这篇文章后,女性的夜宵爱好者们可能需要三思了。这篇近日发表在《JAMA Oncology》(美国医学会杂志-肿瘤学)期刊上的研究表明,每天夜间禁食超过13小时可以降低早期乳腺癌患者的复发几率。


很多人喜欢吃夜宵。不过,在看完这篇文章后,女性的夜宵爱好者们可能需要三思了。这篇近日发表在《JAMA Oncology》(美国医学会杂志-肿瘤学)期刊上的研究表明,每天夜间禁食超过13小时可以降低早期乳腺癌患者的复发几率。

这一结果为何重要

到目前为止,已有一系列的小鼠实验结果显示,进食时间的选择会影响到一些疾病的发病风险。而对于人体,间歇性禁食尽管被发现可降低某些乳腺癌相关风险因素(包括炎症和高血糖),不过其对于乳腺癌的直接影响还是第一次被揭示。

主要的实验结果

来自加州大学圣迭戈分校的研究者们对超过2000名早期乳腺癌女性患者进行了一项为期四年的跟踪调查。在此过程中,研究人员不定期地向受试者进行电话抽查,以记录其在过去24小时内的进食情况,尤其是前一天晚上最后一次进食到第二天早餐之间的间隔时长。结果显示,在排除了其他饮食习惯的影响后,每天夜间禁食少于13小时的受试者的乳腺癌复发率要比禁食更久的个体高出36%,不过其早期死亡率并未明显增高。(注意:由于受跟踪年数限制,患者的长期存活率没有被统计,故只有早期存活率)研究者指出,夜间禁食的时间长短可能通过改变血糖和糖化血红蛋白(HbA1c)的水平从而影响到乳腺癌的复发率。

保留意见

当然,从实验设计的角度,研究者们这次只是通过统计学的手段控制了诸如人口特征、睡眠时间和生理活动等潜在干扰因素。对此,文章的第一作者Catherine Marinac表示,更为理想的实验应是将受试者根据不同夜间禁食时长进行随机分组。

纽约大学西奈山医学院的乳腺癌转化医学主任Charles L. Shapiro博士并没有参与这项研究,但也持类似观点。他表示:“夜间禁食当然不会有什么坏处。然而,根据现有的实验结果,我并不打算向你推荐这种方案,因为这些结果还不能彻底地说服我。”

写在最后

延长夜间禁食时间也许是可以降低乳腺癌的复发率。不过,除此之外,还有其他有着更多证据支持的可以降低乳腺癌复发率的方法,包括增加运动和保持健康的体重。

所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
查看更多
  • Scaling-up treatment of depression and anxiety: a global return on investment analysis

    Background Depression and anxiety disorders are highly prevalent and disabling disorders, which result not only in an enormous amount of human misery and lost health, but also lost economic output. Here we propose a global investment case for a scaled-up response to the public health and economic burden of depression and anxiety disorders. Methods In this global return on investment analysis, we used the mental health module of the OneHealth tool to calculate treatment costs and health outcomes in 36 countries between 2016 and 2030. We assumed a linear increase in treatment coverage. We factored in a modest improvement of 5% in both the ability to work and productivity at work as a result of treatment, subsequently mapped to the prevailing rates of labour participation and gross domestic product (GDP) per worker in each country. Findings The net present value of investment needed over the period 2016–30 to substantially scale up effective treatment coverage for depression and anxiety disorders is estimated to be US$147 billion. The expected returns to this investment are also substantial. In terms of health impact, scaled-up treatment leads to 43 million extra years of healthy life over the scale-up period. Placing an economic value on these healthy life-years produces a net present value of $310 billion. As well as these intrinsic benefits associated with improved health, scaled-up treatment of common mental disorders also leads to large economic productivity gains (a net present value of $230 billion for scaled-up depression treatment and $169 billion for anxiety disorders). Across country income groups, resulting benefit to cost ratios amount to 2·3–3·0 to 1 when economic benefits only are considered, and 3·3–5·7 to 1 when the value of health returns is also included.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test